Dohner et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

Article  PubMed  PubMed Central  Google Scholar 

Hoffman R, Benz EJ, Silberstein LE et al Hematology: Basic principles and practice. Seventh Edition. Philadelphia: Elsevier 2017 Chap. 58: Pathobiology of Acute Myeloid Leukaemia p.919

Popovici-Muller J, Lemieux RM, Artin E et al (2018) Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9(4):300–305

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yen K, Travins J, Wang F et al (2017) AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov 7(5):478–493

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Stein EM, de Botton S et al (2018) Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378(25):2386–2398

Article  CAS  PubMed  Google Scholar 

Stein EM, DiNardo CD, Fathi AT et al (2019) Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133(7):676–687

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roboz GJ, DiNardo CD, Stein EM et al (2020) Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 135(7):463–471

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcuccii G, Maharry K, Wu YZ et al (2010) IDH1 and IDH2 gene mutations identify Novel Molecular subsets within De novo cytogenetically normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 28:2348–2355

Article  Google Scholar 

Paschka P, Schlenk RF, Gaidzik VI et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636–3643

Article  CAS  PubMed  Google Scholar 

Ahmad F, Mohota R, Sanap S, Mandava S, Das BR (2014) Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution Pattern and associations with additional molecular markers in normal Karyotype Indian Acute myeloid leukemia patients. Asian Pac J Cancer Prev 15:1247–1253

Article  PubMed  Google Scholar 

Raveendran S, Sarojam S, Vijay S, Geetha AC, Sreedharan J, Narayan G, Sreedharan H (2015) Mutation analysis of IDH1/2 genes in unselected De novo Acute myeloid leukaemia patients in India - Identification of a novel IDH2 mutation. Asian Pac J Cancer Prev ;16: 4095 – 101

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly patients with Acute myeloid leukemia. Blood 133:7–17

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffioen MS, de Leeuw DC, Janssen JJWM, Smit L (2022) Targeting Acute myeloid leukemia with Venetoclax; biomarkers for sensitivity and rationale for Venetoclax-based combination therapies. Cancers 14:3456

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng JH, Guo XP, Chen YY, Wang ZJ, Cheng YP, Tang YM (2012) Prognostic significance of IDH1 mutations in acute myeloid leukaemia: a meta-analysis. Am J Blood Res 2:254–264

CAS  PubMed  PubMed Central  Google Scholar 

Agarwal A, Jain M, Kushwaha R, Tiwari S, Verma N, Tripathi AK et al (2023) Mutation analysis and clinicopathological implications of isocitrate dehydrogenase 1/2 mutation in Acute myeloid leukemia patients in North India: a tertiary centre based study. Saudi J Pathol Microbiol 8:23–29

Article  Google Scholar 

Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, Fracchiolla NS, Forghieri F, Candoni A, Mengarelli A, Martelli MP, Venditti A, Carella AM, Albano F, Mancini V, Massimo B, Arena V, Sargentini V, Sciumè M, Pastore D, Todisco E, Roti G, Siragusa S, Ladetto M, Pravato S, De Bellis E, Simonetti G, Marconi G, Cerchione C, Fazi P, Vignetti M, Amadori S, Martinelli G, Voso MT (2022) Prevalence and prognostic role of IDH mutations in acute Myeloid Leukemia: results of the GIMEMA AML1516 protocol. Cancers (Basel) 14(12):3012. https://doi.org/10.3390/cancers14123012